Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-SCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy

MLA

Hochmair, Maximilian, et al. “Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-SCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.” Journal of Thoracic Oncology, no. Preprints, Jan. 2024. EBSCOhost, https://doi.org/10.1016/j.jtho.2024.10.012.

APA

Hochmair, M., Schenker, M., Cobo Dols, M., Kim, T. M., Ozyilkan, O., Smagina, M., Viktoriya, L., Kato, T., Fedenko, A., De Angelis, F., Rittmeyer, A., Gray, J. E., Greystoke, A., Aggarwal, H., Huang, Q., Zhao, B., Lara-Guerra, H., & Nadal, E. (2024). Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-SCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy. Journal of Thoracic Oncology, Preprints. https://doi.org/10.1016/j.jtho.2024.10.012

Chicago

Hochmair, Maximilian, Michael Schenker, Manuel Cobo Dols, Tae Min Kim, Ozgur Ozyilkan, Maria Smagina, Leonova Viktoriya, et al. 2024. “Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-SCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.” Journal of Thoracic Oncology, no. Preprints (January). doi:10.1016/j.jtho.2024.10.012.